Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03705403
Recruitment Status : Recruiting
First Posted : October 15, 2018
Last Update Posted : October 20, 2020
Academisch Ziekenhuis Maastricht
The Netherlands Cancer Institute
University Medical Center Nijmegen
Erasmus Medical Center
University Ghent
KU Leuven
Centre Oscar Lambret
Gasthuis Zusters Antwerpen
University College, London
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University Hospital Dresden
University Hospital Tuebingen
Heidelberg University
Catholic University of the Sacred Heart
Institut du Cancer de Montpellier - Val d'Aurelle
Information provided by (Responsible Party):
Maastricht University